WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of DENTSPLY SIRONA Inc. (NASDAQ: XRAY) resulting from allegations that Dentsply Sirona may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Dentsply Sirona securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=6111 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

WHAT IS THIS ABOUT: On April 19, 2022, before market hours, Dentsply Sirona announced that the Company’s Chief Executive Officer had been terminated, effective immediately, and will “cease to serve as a member of the Company’s Board.”

On this news, Dentsply Sirona’s stock fell $6.52, or 13%, to close at $42.20 per share on April 19, 2022, on unusually heavy trading volume, damaging investors.

Then, on May 10, 2022, before market hours, Dentsply Sirona stated that it could not timely file its first quarter 2022 quarterly report due to “an internal investigation of allegations regarding certain financial reporting matters.” Specifically, the investigation concerned “the Company’s use of incentives to sell products to distributors in the third and fourth quarters of 2021 and whether those incentives were appropriately accounted for and the impact of those sales was adequately disclosed.”

On this news, Dentsply Sirona’s stock price fell $2.87 per share, or 7%, to close at $36.38 per share on May 10, 2022, on unusually heavy trading volume, further damaging investors.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success…